FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3011106763> ?p ?o ?g. }

• W3011106763 abstract "Abstract Background Pseudomonas aeruginosa infections are a serious threat in intensive care units (ICUs). The aim of this confirmatory, randomized, multicenter, placebo-controlled, double-blind, phase 2/3 study was to assess the efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in non-surgical ICU patients. Methods Eight hundred patients aged 18 to 80 years admitted to the ICU with expected need for mechanical ventilation for ≥ 48 h were randomized 1:1 to either IC43 100 μg or saline placebo, given in two vaccinations 7 days apart. The primary efficacy endpoint was all-cause mortality in patients 28 days after the first vaccination. Immunogenicity and safety were also evaluated. Findings All-cause mortality rates at day 28 were 29.2% vs 27.7% in the IC43 and placebo groups, respectively ( P = .67). Overall survival (Kaplan-Meier survival estimates, P = .46) and proportion of patients with ≥ one confirmed P. aeruginosa invasive infection or respiratory tract infection also did not differ significantly between both groups. The geometric mean fold increase in OprF/I titers was 1.5 after the first vaccination, 20 at day 28, after the second vaccination, and 2.9 at day 180. Significantly more patients in the placebo group (96.5%) had ≥ one adverse event (AE) versus the IC43 100 μg group (93.1%) ( P = .04). The most frequently reported severe AEs in the IC43 and placebo groups were respiratory failure (6.9% vs 5.7%, respectively), septic shock (4.1% vs 6.5%), cardiac arrest (4.3% vs 5.7%), multiorgan failure (4.6% vs 5.5%), and sepsis (4.6% vs 4.2%). No related serious AEs were reported in the IC43 group. Interpretation The IC43 100 μg vaccine was well tolerated in this large population of medically ill, mechanically ventilated patients. The vaccine achieved high immunogenicity but provided no clinical benefit over placebo in terms of overall mortality. Trial registration https://clinicaltrials.gov ( NCT01563263 ). Registration was sent to ClinicalTrials.gov on March 14, 2012, but posted by ClinicalTrials.gov on March 26, 2012. The first subject was included in the trial on March 22, 2012." @default.
• W3011106763 created "2020-03-23" @default.
• W3011106763 creator A5000153572 @default.
• W3011106763 creator A5006678885 @default.
• W3011106763 creator A5008211273 @default.
• W3011106763 creator A5011470035 @default.
• W3011106763 creator A5013854296 @default.
• W3011106763 creator A5024595069 @default.
• W3011106763 creator A5032741988 @default.
• W3011106763 creator A5033878730 @default.
• W3011106763 creator A5034287216 @default.
• W3011106763 creator A5035752353 @default.
• W3011106763 creator A5041333322 @default.
• W3011106763 creator A5042990512 @default.
• W3011106763 creator A5049053496 @default.
• W3011106763 creator A5051730715 @default.
• W3011106763 creator A5052575923 @default.
• W3011106763 creator A5057787103 @default.
• W3011106763 creator A5058038285 @default.
• W3011106763 creator A5065358331 @default.
• W3011106763 creator A5075431166 @default.
• W3011106763 creator A5080119643 @default.
• W3011106763 creator A5081933142 @default.
• W3011106763 creator A5089975168 @default.
• W3011106763 creator A5091812107 @default.
• W3011106763 date "2020-03-04" @default.
• W3011106763 modified "2023-10-17" @default.
• W3011106763 title "Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients—a randomized clinical trial" @default.
• W3011106763 cites W134787009 @default.
• W3011106763 cites W1881491390 @default.
• W3011106763 cites W1922120322 @default.
• W3011106763 cites W1982931134 @default.
• W3011106763 cites W1985739023 @default.
• W3011106763 cites W1987787962 @default.
• W3011106763 cites W2016711973 @default.
• W3011106763 cites W2024129386 @default.
• W3011106763 cites W2038098936 @default.
• W3011106763 cites W2053059874 @default.
• W3011106763 cites W2068365549 @default.
• W3011106763 cites W2086165685 @default.
• W3011106763 cites W2087692099 @default.
• W3011106763 cites W2103167863 @default.
• W3011106763 cites W2106554965 @default.
• W3011106763 cites W2109038233 @default.
• W3011106763 cites W2120151444 @default.
• W3011106763 cites W2149367169 @default.
• W3011106763 cites W2271079089 @default.
• W3011106763 cites W2412277735 @default.
• W3011106763 cites W2576120252 @default.
• W3011106763 cites W2586033112 @default.
• W3011106763 cites W2789375348 @default.
• W3011106763 cites W3001539821 @default.
• W3011106763 cites W4253391147 @default.
• W3011106763 doi "https://doi.org/10.1186/s13054-020-2792-z" @default.
• W3011106763 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7057595" @default.
• W3011106763 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32131866" @default.
• W3011106763 hasPublicationYear "2020" @default.
• W3011106763 type Work @default.
• W3011106763 sameAs 3011106763 @default.
• W3011106763 citedByCount "39" @default.
• W3011106763 countsByYear W30111067632020 @default.
• W3011106763 countsByYear W30111067632021 @default.
• W3011106763 countsByYear W30111067632022 @default.
• W3011106763 countsByYear W30111067632023 @default.
• W3011106763 crossrefType "journal-article" @default.
• W3011106763 hasAuthorship W3011106763A5000153572 @default.
• W3011106763 hasAuthorship W3011106763A5006678885 @default.
• W3011106763 hasAuthorship W3011106763A5008211273 @default.
• W3011106763 hasAuthorship W3011106763A5011470035 @default.
• W3011106763 hasAuthorship W3011106763A5013854296 @default.
• W3011106763 hasAuthorship W3011106763A5024595069 @default.
• W3011106763 hasAuthorship W3011106763A5032741988 @default.
• W3011106763 hasAuthorship W3011106763A5033878730 @default.
• W3011106763 hasAuthorship W3011106763A5034287216 @default.
• W3011106763 hasAuthorship W3011106763A5035752353 @default.
• W3011106763 hasAuthorship W3011106763A5041333322 @default.
• W3011106763 hasAuthorship W3011106763A5042990512 @default.
• W3011106763 hasAuthorship W3011106763A5049053496 @default.
• W3011106763 hasAuthorship W3011106763A5051730715 @default.
• W3011106763 hasAuthorship W3011106763A5052575923 @default.
• W3011106763 hasAuthorship W3011106763A5057787103 @default.
• W3011106763 hasAuthorship W3011106763A5058038285 @default.
• W3011106763 hasAuthorship W3011106763A5065358331 @default.
• W3011106763 hasAuthorship W3011106763A5075431166 @default.
• W3011106763 hasAuthorship W3011106763A5080119643 @default.
• W3011106763 hasAuthorship W3011106763A5081933142 @default.
• W3011106763 hasAuthorship W3011106763A5089975168 @default.
• W3011106763 hasAuthorship W3011106763A5091812107 @default.
• W3011106763 hasBestOaLocation W30111067631 @default.
• W3011106763 hasConcept C126322002 @default.
• W3011106763 hasConcept C142724271 @default.
• W3011106763 hasConcept C168563851 @default.
• W3011106763 hasConcept C177713679 @default.
• W3011106763 hasConcept C197934379 @default.
• W3011106763 hasConcept C203014093 @default.
• W3011106763 hasConcept C203092338 @default.
• W3011106763 hasConcept C204787440 @default.
• W3011106763 hasConcept C22070199 @default.
• W3011106763 hasConcept C27081682 @default.
• W3011106763 hasConcept C2776376669 @default.

• next